Codexis, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith from TD Cowen maintained a Hold rating on the stock and has a $2.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Brendan Smith has given his Hold rating due to a combination of factors, including Codexis’ solid Q1 performance and the dependence on future execution. The company exceeded revenue expectations largely because of the Merck transfer-related contribution and reaffirmed its long-term targets, but much of the growth story still hinges on securing new CDMO and pharma partnerships and translating its ECO platform into recurring revenue.
While management’s view of a sizable siRNA manufacturing opportunity and the potential differentiation from stereochemical control are encouraging, these remain early-stage validation and commercialization efforts. The upcoming TIDES presentation, planned GMP facility retrofit, and scale-up to half-kilo production are important milestones, yet the timing and magnitude of their impact are uncertain, supporting a neutral stance and an unchanged $2 price target.